PROGRAM COMMITTEE CHAIRSSophie Deng, MD, PhDChair, Cornea SocietyScientific ProgramJules Stein Eye Institute, UCLALos Angeles, CAMarjan Farid, MDChair, EBAA Scientific ProgramsUniversity of California, IrvineIrvine, CAPROGRAM COMMITTEE MEMBERSMaria SoledadCortina, MDUniversity of Illinois,ChicagoChicago, ILJoshua H. Hou, MDJoung Kim, MDAhmed Omar, MDUniversity of MinnesotaMinneapolis, MNEmory Eye CenterAtlanta, GAUniversity Hospitals EyeInstituteCleveland, OHC. Drew Salisbury,MDPremier Medical GroupAtlanta, GADavid D. Verdier, MDVerdier Eye Center, PLCGrand Rapids, MIAsim Farooq, MDBennie H. Jeng, MDJennifer Y. Li, MDCorrina PatzerChristine Shieh, MDUniversity of ChicagoChicago, ILUniversity of MarylandSchool of MedicineBaltimore, MDUniversity of California,DavisSacramento, CALions VisionGiftPortland, ORVanderbilt Eye InstituteNashville, TNJoann Kang, MDMarian S. Macsai,MDSaira Quraishy, CEBTDivya Srikumaran,MDGregory Grossman,PhD, CEBTAdvancing SightNetworkBirmingham, ALAlbert Einstein CollegeNew York, NYOyster Point PharmaChicago, ILGeorgia Eye BankAtlanta, GAWilmer Eye InstituteBaltimore, MDPedram Hamrah, MDAdam Kaufman, MDPriya Mathews, MDMichelle K. Rhee, MDMichael Titus, CEBTTufts Medical CenterBoston, MAUniversity of CincinnatiMedical CenterCincinnati, OHFlorida Eye Specialists &Cataract InstituteTampa, FLIcahn School of Medicineat Mount SinaiNew York City, NYEversightAnn Arbor, MINEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021


PROGRAM FACULTYEsen Akpek, MDAndrea Blitzer, MDJohns HopkinsUniversityBaltimore. MDUniversity of IowaIowa City, IAAnthony Aldave,MDClémence Bonnet,MDStein Eye Institute,UCLALos Angeles, CAStein Eye Institute,UCLALos Angeles, CAHamid Alemi, MD,MPHWinstonChamberlain, MD,PhDKathryn Colby,MD, PhDNYU Langone HealthNew York, NYJulie Daniels, PhDUniversity CollegeLondonLondon, UKSophie Deng, MD,PhDMaria A.Henriquez, MD,MSc, PhDStephen C.Kaufman, MD, PhDValeria OlivaBiénzobas, MDAdam Wylegala,MD. DMS. FEBO.University ofMinnesotaMinneapolis, MNCentro de la VisionSantiago, LoBarnecheaBascom Palmer EyeInstituteMiami, FLVincent Hussey,MSAnne-MarieKladny, MDOnkar Sawant,PhDMadeline Yung,MDUniversity ofCalifornia, IrvineSanta Ana, CAUniversity of FreiburgFreiburg, BadenWürttembergEversightCleveland, OHUniversity ofCalifornia, DavisVacaville, CAUla Jurkunas, MDViridiana Kocaba,MD, PhD, FEBOMichael Szkarlat,BSNetherlands Institutefor Innovative OcularSurgery (NIIOS)Rotterdam, SouthHollandEversightAnn Arbor, MIBascom Palmer EyeInstitute, University ofMiamiMiami, FLRoza Vaez Ghaemi,PhDMichael Zilliox,PhDUniversity of BritishColumbiaVancouver, BCLoyola UniversityChicagoMaywood, ILOftalmosalud Institutode OjosLima, PeruStein Eye Institute,UCLALos Angeles, CASchepensEye Institute/Massachusetts Eyeand EarBoston, MAJessica Chen, MDMarjan Farid, MDSteven Kane, MDJennifer Li, MDDevers Eye InstitutePortland, ORUniversity ofCalifornia, IrvineIrvine, CATailored EyesVenice, FLUniversity ofCalifornia, Davis/Sierra Donor ServicesEye BankSacramento, CABalamurali Ambati,MD, PhDJoseph B. Ciolino,MDMatthew Hartman,MDAaron R. Kaufman,MDPacific Clear VisionInstituteEugene, ORMassachusetts Eyeand EarBoston, MASoutheast EyeSpecialistsBrentwood, TNUniversity of Illinois atChicago/ Illinois Eyeand Ear InfirmaryChicago, ILJodhbir Mehta,MBBS, PhD,FRCOphth, FRCS(Ed), FAMSSchepens EyeResearch Institute/Massachusetts Eyeand EarBoston, MAJorge Alió, MD, PhD,FEBOUniversity MiguelHernández of ElcheAlicante, SpainOregon Health &Science UniversityPortland, ORSingapore NationalEye CentreSingaporeNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021Fasika Woreta,MD, MPHWilmer Eye InstituteBaltimore, MDAngela Zhu, MD


BOARD OF DIRECTORSNoel MickChairThe Eye-Bank for SightRestorationEric Meinecke, CEBTAt-Large MemberGeorgia Eye BankJennifer Li, MDChair-ElectSierra Donor ServicesEye BankStephen Kaufman, MD,PhDAt-Large MemberLions Gift of SightKevin Corcoran, CAEPresident & CEOEye Bank Association ofAmericaElizabeth FoutSecretary/TreasurerFlorida Lions Eye BankBrian Philippy, CEBT,BCHEAt-Large MemberLions Medical Eye Bank& ResearchCenter of EasternVirginiaDean Vavra, MS, CEBT,COTSpeaker of the HouseMiracles in SightShahzad Mian, MDAt-Large MemberEversightWoodford Van Meter,MDImmediate Past ChairKentucky Lions EyeBankMegan YoungAt-Large MemberSan Diego Eye BankChris Hanna, MBA,CEBTAt-Large MemberUtah Lions Eye BankWinston D.Chamberlain, MD, PhDMedical Advisory BoardChairLions Vision GiftNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

BOARD OF DIRECTORSKathryn Colby, MD,PhDPresidentNYU Grossman Schoolof MedicineNew York, NYBennie Jeng, MDVice PresidentPresident-ElectUniversity of MarylandSchool of MedicineBaltimore, MDElmer Tu, MDPast PresidentUniversity of Illinois ChicagoChicago, ILWilliam Barry Lee, MDSecretaryEye Consultants ofAtlantaAtlanta, GAWoodford Van Meter,MDTreasurerUK HealthCareLexington, KYAnthony Aldave, MDVice President forInternational RelationsUCLA Stein Eye InstituteLos Angeles, CADeepinder Dhaliwal, MDVice President forIndustry RelationsUniversity of PittsburghSchool of MedicinePittsburgh, PASophie X. Deng, MD,PhDScientific Program ChairUCLA Stein Eye InstituteLos Angeles, CAMia Woodward, MDAAO CouncilorUniversity of MichiganKellogg Eye CenterAnn Arbor, MIJessica Ciralsky, MDBoard Member-At-LargeWeill Cornell MedicineOphthalmologyNew York, NYJose Gomes, MDBoard Member-At-LargeSão Paulo, BrazilJosé Güell, MDBoard Member-At-LargeInstituto de MicrocirugíaOcularBarcelona, SpainVishal Jhanji, MDBoard Member-At-LargeUniversity of PittsburghMedical CenterPittsburgh, PAParag A. Majmudar, MDBoard Member-At-LargeChicago CorneaConsultants, Ltd.Chicago, ILJod Mehta, MDBoard Member-At-LargeSingapore National EyeCenter (SNEC)SingaporeShahzad Mian, MDBoard Member-At-LargeUniversity of MichiganKellogg Eye CenterAnn Arbor, MISonal Tuli, MDBoard Member-At-LargeUniversity of FloridaCollege of MedicineGainesville, FLNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021


SUPPORTThe Eye Bank Association of America and the Cornea Society gratefully acknowledge the unrestricted educationalgrants received in support of this program.BEST PAPER OF SESSION AWARDLions Gift of SightGENERAL EDUCATIONAL GRANTMed-Logics, Inc.Wolters KluwerNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

– –Run from Anywhere!Virtual 5K Run/WalkNovember


LEARNER NOTIFICATIONEBAA/ Cornea Society2021 Cornea & Eye Banking ForumNovember 12, 2021Astor Crowne Plaza - New Orleans, LACEBTSAcknowledgement of Financial Commercial SupportOBJECTIVES – AFTER ATTENDING THISPROGRAM YOU SHOULD BE ABLE TO Lions Gift of Sight Med-Logics, Inc. Wolters KluwerEye Bank Association of America approves thisactivity for a maximum of 7 CEUs. An evaluation willbe sent to CEBTs following the event, the evaluationmust be completed to receive credit for attending.1. Learn new developments, techniques andtherapies in sight restoration.2. Analyze the efficacy of emerging technologiesand innovative processes in cornealtransplantation and eye banking that can improvepatient outcomes.ACKNOWLEDGEMENT OF IN-KINDCOMMERCIAL SUPPORTNo in-kind commercial support was received for thiseducational activity.3. Cite new research findings in cornea regardingdisease, treatment, transplantation, preservation,preparation and processing.SATISFACTORY COMPLETIONLearners must complete an evaluation form toreceive a certificate of completion. Partial creditof individual sessions is not available. If you areseeking continuing education credit for a specialtynot listed below, it is your responsibility to contactyour licensing/certification board to determine courseeligibility for your licensing/certification requirement.ACCREDITATION STATEMENTHOW TO GET YOUR CERTIFICATE1.Go to http://EBAA.cmecertificateonline.com2. Click on the “2021 Cornea & Eye Banking Forum”link.3.Evaluate the meeting.4. Print all pages of your certificate for your records.In support of improving patient care, this activity hasbeen planned and implemented by Amedco LLC andCornea Society. Amedco LLC is jointly accreditedby the Accreditation Council for Continuing MedicalEducation (ACCME), the Accreditation Council forPharmacy Education (ACPE), and the American NursesCredentialing Center (ANCC), to provide continuingeducation for the healthcare teamQuestions? Email [email protected] LLC designates this live activity for amaximum of 8.5 AMA PRA Category 1 CreditsTM.Physicians should claim only the credit commensuratewith the extent of their participation in the activity.NEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

FINANCIAL INTEREST DISCLOSURESDISCLOSURE OF CONFLICT OF INTERESTThe following table of disclosure information is provided to learners and contains the relevant financial relationshipsthat each individual in a position to control the content disclosed to Amedco. All of these relationships were treated asa conflict of interest, and have been resolved. (C7 SCS 6.1- ‐6.2, 6.5)All individuals in a position to control the content of CE are listed below.FIRST NAME LAST NAMECOMMERCIAL INTERESTNatalieAfshariTrefoil Therapeutics: ConsultantClaris Biotherapeutics: ConsultantAlpine Biotherapeutics: Stock ShareholderGSK: ConsultantDompe: ConsultantAescula Tech: ConsultantEyeYon: ConsultantEsenAkpekNovartis: Research Grant Overall Principal InvestigatorOcular Therapeutics: Research Grant Overall Principal InvestigatorW.L. Gore, Inc: Research Grant Overall Principal InvestigatorRegeneron Healthcare Solutions Inc: Research Grant Site PrincipalInvestigatorNational Eye Institute: Research Grant Site Principal InvestigatorDompe: ConsultantEpitech: ConsultantFirstString Medical Research: ConsultantNovalique: ConsultantShire: ConsultantSinqi: ConsultantHanAll: ConsultantAdelphi Values: ConsultantRegeneron Healthcare Solutions, Inc.: ConsultantUp-to-date: PatentSjogren’s Foundation: Unpaid member of Board of Directors and ConsultantAnthonyAldaveCorneaGen: ConsultantAsimAliSanten: ConsultantBalamuraliAmbatiiVeena: Stock ShareholderNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

FINANCIAL INTEREST DISCLOSURESBrandonAyresAllergan: Speakers BureauAlcon: Speakers BureauBausch & Lomb: Speakers BureauShire: ConsultantOmeros: ConsultantKala: ConsultantEye Point: ConsultantZeiss: ConsultantLamisBaydounDORC International BV/Dutch Ophthalmic USA: ConsultantPeterBedardBrightStar Therapeutics: Patent HolderWinstonChamberlainOyster Point Pharma: Scientific/Medical Advisory Board MemberLeo Pharma: Scientific/Medical Advisory Board MemberAslan Pharmaceuticals: Scientific/Medical Advisory Board MemberCambium Medical Technologies: Scientific/Medical Advisory Board MemberSunilChauhanClaris Bio: Stock ShareholderAramis Bio: Stock ShareholderJosephCiolinoORA: ConsultantTherOptix: Stock ShareholderKathrynColbyGlaxo Smith Kline: ConsultantWL Gore, Inc: ConsultantKowa: Research Grant Overall Principal InvestigatorKowa: Research Grant Site Principal InvestigatorRezaDanaNovartis: ConsultantAramis Biosciences: Stock ShareholderKera Therapeutics: Stock ShareholderBoston Eye Diagnostics: Stock ShareholderClaris Biotherapeutics: Stock ShareholderDOD-CDMRP: Research Grant Site Principal InvestigatorKala: ConsultantNIH R01 12963: Research Grant Site Principal InvestigatorNIH R21 EY029387: Research Grant Site Principal InvestigatorNIH R01 20889: Research Grant Site Principal InvestigatorGelMEDIX: Stock ShareholderGSK: ConsultantKarenDeMarcoLions Eye Institute for Transplant and Research: EmployeeSophieDengDompe: ConsultantClaris Biotherapeutics: Scientific/Medical Advisory Board MemberNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

FINANCIAL INTEREST DISCLOSURESAliDjalilianNovartis: ConsultantCombangio: ConsultantMarjanFaridJohnson & Johnson Vision: ConsultantKALA: ConsultantNovartis: ConsultantAllergan: ConsultantBiotissue: ConsultantCorneaGen: ConsultantSightLife: Corporate Board MemberDompe: ConsultantBaush and Lomb: ConsultantZeiss: ConsultantTarsus: ConsultantAsimFarooqGlaxoSmithKline: ConsultantAmgen: ConsultantAmbrx: ConsultantElizabethFoutFlorida Lions Eye Bank: EmployeeSimonFungDompe: Research Grant Overall Principal InvestigatorSanten: ConsultantDaiichi: ConsultantAndreasGlatzOculus, Wetzlar, Germany: OtherFarhadHafeziEMAGine AG: Stock ShareholderPedramHamrahDompe: Research Grant Site Principal InvestigatorCoopervision: Research Grant Site Principal InvestigatorShire: Research Grant Site Principal InvestigatorAllergan: Research Grant Site Principal InvestigatorOKYO: Research Grant Site Principal InvestigatorNational Eye Institute: Research Grant Site Principal InvestigatorSanten: ConsultantOcunova: ConsultantOKYO: ConsultantNovartis: Research Grant Overall Principal InvestigatorNovaliq: Scientific/Medical Advisory Board MemberDompe: Scientific/Medical Advisory Board MemberNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

FINANCIAL INTEREST DISCLOSURESEdwardHollandHanall, Hovione, IanTECH, Imprimis Pharma: ConsultantInvirsa, Johnson & Johnson Vision Care, Kala Pharmaceuticals: ConsultantKatena, KeraKlear, Licrieye, Mati Pharmaceuticals: ConsultantMerck KGgA,MG Thera, Mintz, Nanowafer, Inc: ConsultantNovaliq, Novartis NIBR, Novartis Pharmaceuticals: ConsultantNovartis Surgical, Ocunexus, Ocuphire, Omeros: ConsultantOphthotech, Oyster Point, Precise Bio, Prometic: ConsultantReGenTree, LLC, Retear, Senju, Shire, Sight Sciences: ConsultantSightLife, Silktech, Slack, Stuart Therapeutics, Takeda Coordination, Tarsus,Tearfilm Innovations, TearLab, TissueTech, Topivert Pharma Limited, Vomaris,WL Gore and Associates, Zeiss: ConsultantJoshuaHouBrightstar Therapeutics: Patent HolderSandeepJainOcugen, Inc: ConsultantNeutrolis, Inc: ConsultantAdvaite, Inc: Corporate Board MemberSelagine, Inc: Stock ShareholderBennieJengOyster Point Pharma: ConsultantUlaJurkunasKowa Grant Support: Research Grant Site Principal InvestigatorSteveKaneBiotissue: ConsultantAdamKaufmanAlcon: Consultant1800Contacts: ConsultantBausch & Lomb: ConsultantW. BarryLeeNovartis: Speakers BureauGore Pharmaceuticals: ConsultantBioTissue: Speakers BureauDompe: ConsultantJohnson & Johnson: ConsultantEyeVance: ConsultantMarianMacsaiTrefoil: ConsultantAllergan: ConsultantInversa: ConsultantGlaukos: Scientific/Medical Advisory Board MemberNovartis: Speakers BureauBruder: Scientific/Medical Advisory Board MemberEyevance: Stock ShareholderOyster Point Pharma: EmployeePriyaMathewsW. L. Gore and Associates: ConsultantSun Pharmaceutical: Speakers BureauNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

FINANCIAL INTEREST DISCLOSURESEricMeineckeGeorgia Eye Bank:EmployeeShahzadMianKOWA: Research Grant Site Principal InvestigatorVisionCare: Research Grant Site Principal InvestigatorDOD: Research Grant Site Principal InvestigatorNovartis: Research Grant Site Principal InvestigatorAndover Eye Associates: Research Grant Site Principal InvestigatorKamiarMireskandariBayer: Research Grant Site Principal InvestigatorSanten Canada Inc: Scientific/Medical Advisory Board MembeNovartis: Scientific/Medical Advisory Board MemberVictorPerezAlcon: Research Grant Overall Principal InvestigatorEyeGate: Scientific/Medical Advisory Board MemberKala: ConsultantNovartis: Scientific/Medical Advisory Board MemberNovartis: Research Grant Site Principal InvestigatorEyeGate: Stock ShareholderTrefoil: Scientific/Medical Advisory Board MemberTrefoil: Stock ShareholderChristinaPrescottJohnson and Johnson Vision: ConsultantSanten: ConsultantMichelle K.RheeOcular Therapeutix: Research Grant Site Principal InvestigatorNovaBay: Scientific/Medical Advisory Board MemberCynthiaRobertsOculus: ConsultantZiemer: ConsultantAlfonsoSabaterTissueCor, LLC: Stock ShareholderDivyaSrikumaranAlcon: ConsultantMichaelStraikoWL Gore: ConsultantMichaelSzkarlatEversight: EmployeeMichaelTaravellaInnovia Medical: OtherMarkTerryBausch & and Lomb Surgical: Patent HolderMoria: Unrestricted Educational Grant for Annual EKG BreakfastMichaelTitusEversight: EmployeeNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

FINANCIAL INTEREST DISCLOSURESElmerTuEversight: Scientific/Medical Advisory Board MemberGSK: ConsultantOyster Point Pharma: Scientific/Medical Advisory Board MemberDaiichi Sankyo: ConsultantDompe: ConsultantKatrinWackerProQR Therapeutics, the Netherlands: ConsultantJiaYinKera Therapeutics: OwnerChingYuanBrightStar Therapeutics: Patent HolderMadelineYungEBAA Pilot Research Grant: Research Grant Overall Principal InvestigatorNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021


PROGRAM SCHEDULERegistration: 7:00 am – 2:00 pmBreakfast:7:00 am – 8:00 amSECTION I8:00 am – 8:03 amWelcome and IntroductionsSophie Deng, MD, PhD, and Marjan Farid, MD8:04 am – 8:50 amINVITED SESSION: FUTURE OF THE TREATMENT OF CORNEAL ENDOTHELIALAND STROMAL DISEASEPresenters:Jorge Alió, MD, PhD, FEBO, University Miguel Hernández of ElcheKathryn Colby, MD, PhD, NYU Langone HealthUla Jurkunas, MD, Mass Eye and EarJodhbir Mehta, MBBS, FRCOphth, FRCS(Ed), FAMS, PhD, Singapore National EyeCentre8:51 am – 9:02 amTopical Ivmed-80 Eyedrops for Pharmacologic Crosslinking of Keratoconuswithout UV Light or SurgeryBalamurali Ambati, MD, PhD, Pacific Clear Vision Institute9:03 am – 9:14 amNicergoline: A Potential Novel Treatment for Severe Persistent Corneal EpithelialDefectsValeria Oliva-Biénzobas, MD, Centro de la Vision9:15 am – 9:26 amTopical 1% 5-fluorouracil as Primary Treatment for Ocular Surface SquamousNeoplasia: Long-Term Follow-up StudyAdam Wylegala, MD, DMS, FEBO,** Bascom Palmer Eye Institute9:27 am – 9:38 amPhlyctenular Disease Associated with Increased Incidence and Severe CornealSequelae in Hispanic Pediatric PatientsAaron R. Kaufman, MD,* University of Illinois at Chicago, Illinois Eye and Ear Infirmary9:39 am – 9:50 amOutcomes of Fluid-Filled Scleral Lens Devices for the Management of LimbalStem Cell DeficiencyClémence Bonnet, MD, Stein Eye Institute, UCLA9:51 am – 10:05 amCornea Society Business Meeting10:05 am – 10:20 amBreak* ResidentNEW ORLEANS,LAFRIDAY, NOVEMBER12** CorneaFORUM 2021Fellow

PROGRAM SCHEDULESECTION II10:20 am – 10:21 amWelcome BackMarjan Farid, MD, and Sophie Deng, MD, PhD10:22 am – 10:24 am2021 EBAA High Impact Research Grant Award AnnouncementBennie Jeng, MD, Chair, EBAA Research Committee10:25 am – 10:36 amEffect of Increasing Povidone Iodine (PVP-I) Exposure on Tissue Quality andImpact on Donor Rim CulturesOnkar Sawant, PhD, Eversight10:37 am – 10:48 amDouble Povidone Iodine Wash: Effectivity in Reducing the Infection Rate ofRecovered Corneal TissueStephen C. Kaufman, MD, PhD, University of Minnesota10:49 am – 11:00 amInduction of Antimicrobial Peptide Expression in Human Donor Corneas UsingAndrographolideMadeline Yung, MD, University of California, Davis11:01 am – 11:12 amThe Impact of Amphotericin B Fortified Preservation Media on Rates ofEndothelial Keratoplasty DetachmentVincent Hussey, MS, University of California, Irvine11:13 am – 11:24 amEndophthalmitis Rates Following Cornea Surgery in the Medicare Populationfrom 2016 to 2019Fasika Woreta, MD, MPH, Wilmer Eye Institute11:25 am – 11:36 amThe Microbiome in Stevens-Johnson SyndromeMichael Zilliox, PhD, Loyola University Chicago11:37 am – 11:41 amR. Townley Paton IntroductionStephen C. Kaufman, MD, PhD, 2020 R. Townley Paton Award RecipientMark Mannis, MD, 1996 R. Townley Paton Award Recipient11:42 am – 12:05 pmR. Townley Paton Lecture: Well-Behaved Women Seldom Make History:The Advancement of Women in OphthalmologyJennifer Li, MD, 2021 R. Townley Paton Award Recipient12:06 pm – 12:10 pmClosing MedicalNEW ORLEANS,LA StudentFRIDAY, NOVEMBER 12FORUM 2021

PROGRAM SCHEDULER. TOWNLEY PATON LUNCHEON12:15 pm – 1:25 pmR. Townley Paton LuncheonIncludes a seated lunch and a moderated discussion. Physician attendees are invited.SECTION III1:30 pm – 1:31 pmAfternoon Session WelcomeSophie Deng, MD, PhD, and Marjan Farid, MD1:32 pm – 1:43 pmDescemet Membrane Endothelial Keratoplasty (DMEK): 10-year ClinicalOutcomes and Graft SurvivalViridiana Kocaba, MD, PhD, FEBO, Netherlands Institute for Innovative OcularSurgery (NIIOS)1:44 pm – 1:55 pmTwo Year Changes in Corneal Power after Endothelial Keratoplasty: Results fromthe Randomized Controlled DETECT TrialWinston Chamberlain, MD, PhD, Oregon Health & Science University1:56 pm – 2:07 pmPrimary Graft Failure Following Descemet Membrane Endothelial KeratoplastyUsing Nondiabetic Donor TissueAndrea Blitzer, MD,** University of Iowa2:08 pm – 2:19 pmDoes the Size and Duration of the Bubble in DMEK Surgery Affect theAttachment and Endothelial Cell Loss of the DMEK Graft?Jessica Chen, MD,** Devers Eye Institute2:20 pm – 2:31 pmComparison of Graft Viability in Tri-Folded Endothelium-In and ScrolledEndothelium-Out Preloaded Descemet Membrane Endothelial KeratoplastyMatthew Hartman, MD, Southeast Eye Specialists2:32 pm – 2:43 pmDifference in Postoperative Graft Adherence Between Descemet MembraneEndothelial Keratoplasty with and without Cataract SurgeryAnne-Marie Kladny, MD,* University of Freiburg2:44 pm – 2:55 pmNovel Preloaded Injectable UT-Descemet’s Stripping Automated EndothelialKeratoplasty (UT-DSAEK): No Touch Surgical Technique and Early Surgical ResultsSteven Kane, MD, Tailored Eyes2:56 pm – 3:07 pmAn Alternative Time Efficient Method to Specular Microscopy Following DMEKPreparation Using Trypan Blue StainingMichael Szkarlat, BS, Eversight* ResidentNEW ORLEANS,LAFRIDAY, NOVEMBER12** CorneaFORUM 2021Fellow

PROGRAM SCHEDULE3:08 pm – 3:10 pmRichard Troutman Prize Award IntroductionKathryn Colby, MD, PhD, NYU Langone Health3:11 pm – 3:20 pmRichard Troutman Prize Lecture: Accelerated Epi-On Versus StandardEpi-Off Corneal Collagen Cross-Linking for Progressive Keratoconus in PediatricPatients: Five Years of Follow-UpMaria A. Henriquez, MD, MSc, PhD, Oftalmosalud Instituto de Ojos3:20 pm – 3:35 pmBreakSECTION IV3:35 pm – 3:36 pmWelcome BackMarjan Farid, MD, and Sophie Deng, MD, PhD3:37 pm – 4:07 pmINVITED SESSION: Future of Artificial CorneaPresenters:Esen Akpek, MD, Johns Hopkins UniversityJulie Daniels, PhD, University College LondonAnthony Aldave, MD, Stein Eye Institute, UCLA4:08 pm – 4:19 pmRegulatory T-cells Promote Corneal Graft Survival by Modulating PostTransplantation Alloimmune ResponseHamid Alemi, MD, MPH, Schepens Eye Research Institute/ Massachusetts Eye andEar4:20 pm – 4:31 pmAssociation Between Anti-Human Leukocyte Antigen (HLA) Antibodies and GraftRejection in Pediatric KeratoplastyAngela Zhu, MD, Bascom Palmer Eye Institute, University of Miami4:32 pm – 4:43 pmHyaluronic-Acid Based Bioengineered Corneal Stromal SubstituteRoza Vaez Ghaemi, PhD, University of British Columbia4:44 pm – 4:55 pmProspective, Randomized, Multicenter, Double-Masked, Clinical Trial EvaluatingCorneal Crosslinking of Keratoprosthesis Carrier TissueJoseph B. Ciolino, MD, Schepens Eye Institute/ Mass Eye and Ear4:56 pm – 4:59 pmBest Paper of Session Award PresentationSupported by an unrestricted educational grant from Lions Gift of Sight5:00 pmClosing RemarksSophie Deng, MD, PhD, and Marjan Farid, MDNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021



INVITED SESSIONSFuture of the Treatment of Corneal Endothelialand Stromal DiseaseSECTION I: 8:04 AM – 8:50 AMUtilizing Mesenchymal Stem Cells for the Treatment of KeratoconusJorge Alió, MD, PhD, FEBO, University Miguel Hernández of ElcheCurrent Status of Descemet Stripping Only (DSO)Kathryn Colby, MD, PhD, NYU Langone HealthAntioxidant Treatments for Fuchs Dystrophy: What is New?Ula Jurkunas, MD, Mass Eye and EarCultivated Endothelial Cell Sheets for Endothelial FailureJodhbir Mehta, MBBS, FRCOphth, FRCS(Ed), FAMS, PhD, Singapore National Eye CentreModerated Q&AAll presentersFuture of Artificial CorneaSECTION IV: 3:37 PM- 4:07 PMThe Predicted Future of the Artificial Cornea and Where are We Headed?Anthony Aldave, MD, Stein Eye Institute, UCLABiocompatibility of a Novel Synthetic Corneal DeviceEsen Akpek, MD, Johns Hopkins UniversityCornea Equivalent for the Treatment of Stromal DiseaseJulie Daniels, PhD, University College LondonModerated Q&AAll presentersNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021


AWARD LECTURESR. TOWNLEY PATON AWARD LECTUREWell-Behaved Women Seldom Make History:The Advancement of Women in OphthalmologyJennifer Li, MD, University of California, Davis/Sierra Donor Services Eye Bank2021 R. Townley Paton Award RecipientApproximately 150 years ago, Isabel Hayes Chapin Barrows became the first woman to practiceophthalmology in the United States. Since that time, women have made tremendous strides withinophthalmology. During this year’s Paton Lecture, we will celebrate the pioneering women who havehelped pave the way for us, and reflect on how far we have come in our efforts to break down the gendergap. We will also explore areas where further progress is still needed for women in ophthalmology.RICHARD TROUTMAN PRIZE LECTUREAccelerated Epi-On Versus Standard Epi-Off CornealCollagen Cross-Linking for Progressive Keratoconus inPediatric Patients: Five Years of Follow-Up*Maria A. Henriquez, MD, MSc, PhD, Oftalmosalud Instituto de OjosCo-Authors: Gustavo Hernandez-Sahagun, MD, Jorge Camargo, MD, and Luis Izquierdo, Jr, MD, MSc, PhDPurpose: The purpose of this study was to evaluate and compare the 5-year efficacy and safety ofaccelerated transepithelial (A-epi-on) corneal collagen cross-linking (CXL) with standard CXL (epi-off) inchildren with progressive keratoconus (KC).Methods: This prospective cohort study included 78 eyes of patients aged 18 years old or younger withprogressive KC who underwent CXL at the Oftalmosalud Institute of Eyes, Lima, Peru. A-epi-on CXL wasperformed in 32 eyes (309 of impregnation/59 of irradiation at 18 mW/cm2) and epi-off CXL was performedin 46 eyes (309of impregnation/309 minutes of irradiation at 3 mW/cm2). Visual acuity, refraction, and theScheimpflug imaging parameters were evaluated preoperatively and postoperatively at 1 and 5 years.Results: The best corrected visual acuity improved to 0.06 logarithm of the minimum angle of resolution(SD: 0.19, P 0.03) and 0.09 logarithm of the minimum angle of resolution (SD: 0.13, P, 0.001) in the A-epion and epi-off groups, respectively. The mean flattening in the mean keratometry was 0.09 diopters (D)(SD: 0.68, P 0.33) and 3.18 D (SD: 5.17, P, 0.001) in the A-epi-on CXL and Epi-off groups at the 5-yearfollow-up. Significant differences were found in the change at 1 and 5 years between the groups forcylinder reduction, flat and mean K, and pachymetry (all P, 0.05). The KC progression rate was 9.37%(3/32) in the A-epi-on CXL; no progression was found in the epi-off CXL group at the 5-year follow-up.Conclusions: Both procedures halted the progression of KC at the 5-year follow-up; however, epi-offCXL was safer and more effective when compared with A-epi-on CXL.*Originally published in Cornea Volume 39, Number 12, December 2020NEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021


SCIENTIFIC ABSTRACT8:51 am – 9:02 amTopical Ivmed-80 Eyedrops for Pharmacologic Crosslinking of Keratoconus without UV Lightor SurgeryBalamurali Ambati, MD, PhD, Pacific Clear Vision InstituteCo-Authors: Sarah Molokhia, PhD; Hironori Uehara, PhD; Arturo Chayet, MD; Cynthia Roberts, PhD; Sabine Kling, PhD;and Farhad Hafezi, PhDPurpose: To determine whether IVMED-80 eyedrops, which increase lysyl oxidase, can flatten the cornea in patientswith keratoconus.Methods: Pre-clinical IVMED-80 studies determined if it increased LOX activity of keratoconic fibroblasts and rabbitcorneas, improved human donor and rabbit corneal biomechanics, and flattened rabbit corneas. A Phase 1/2aprospective, randomized, double-masked, controlled trial was performed to determine the safety and preliminaryefficacy of BID dosing of IVMED-80 eyedrops ind 36 patients with a history of progressive keratoconus, between18 to 42 years of age. Three subarms included vehicle control, 6 and 16 weeks of therapy, with 6 months follow-up.Endpoints included Kmax, BCVA, endothelial cell count, IOP, and adverse event analysis.Results: IVMED-80 increased LOX activity of fibroblasts 4-fold, and flattened rabbit corneas by 1.8 diopters with 6weeks of treatment. Four month clinical trial follow-up data is currently available. In patients (mean age of 27.3 /- 6.8years), we observed flattening of Kmax by 1.0 diopters in the 16 week therapy group, while the 6 week therapy grouphad initial flattening of 0.40 diopters at 1 month, but rebounded to baseline by month 4. Vehicle-treated patientsdemonstrated continued progression. No significant changes on BCVA, endothelial cell count, or IOP were observed.No adverse events were observed.Conclusion: IVMED-80 induces pharmacologic crosslinking by delivering copper to increase corneal LOX, whichgenetic and biochemical studies show is reduced in keratoconus. We demonstrate improved donor and rabbit cornealbiomechanics, and flattening of rabbit corneas. IVMED-80 reduced Kmax of 1.0 D with 16 weeks of therapy in patientswithout adverse events.NEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

SCIENTIFIC ABSTRACT9:03 am – 9:14 amNicergoline: A Potential Novel Treatment for Severe Persistent Corneal Epithelial DefectsValeria Oliva-Biénzobas, MD, Centro de la VisionCo-Authors: Alejandro Navas; Victor Boullosa; A

Albert Einstein College New York, NY Marian S. Macsai, MD Oyster Point Pharma Chicago, IL Saira Quraishy, CEBT Georgia Eye Bank Atlanta, GA Divya Srikumaran, MD Wilmer Eye Institute Baltimore, MD Pedram Hamrah, MD Tufts Medical Center Boston, MA . Chamberlain, MD, PhD Medical Advisory Board